Source: National Library of Medicine

Conclusion: Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.

Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial

Philippe Gautret 1Jean-Christophe Lagier 2Philippe Parola 1Van Thuan Hoang 3Line Meddeb 4Morgane Mailhe 4Barbara Doudier 4Johan Courjon 5Valérie Giordanengo 6Vera Esteves Vieira 4Hervé Tissot Dupont 2Stéphane Honoré 7Philippe Colson 2Eric Chabrière 2Bernard La Scola 2Jean-Marc Rolain 2Philippe Brouqui 2Didier Raoult 8Affiliations expand

Abstract

Background: Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads.

Patients and methods: French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16th, to receive 600mg of hydroxychloroquine daily and their viral load in nasopharyngeal swabs was tested daily in a hospital setting. Depending on their clinical presentation, azithromycin was added to the treatment. Untreated patients from another center and cases refusing the protocol were included as negative controls. Presence and absence of virus at Day6-post inclusion was considered the end point.

Results: Six patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight had lower respiratory tract infection symptoms. Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination.

Conclusion: Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.

Keywords: 2019-nCoV; COVID-19; SARS-CoV-2; azithomycin; clinical trial; hydroxychloroquine.

Copyright © 2020. Published by Elsevier B.V.

Conflict of interest statement

Declaration of Competing Interest N/A

Figures

Figure 1
Figure 2

See the original here: https://pubmed.ncbi.nlm.nih.gov/32205204/

See related articles:

Latest treatment results from the IHU pre-publication site on COVID-19. 1061 patients, 91% effective

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »

The Chloroquine Wars Part XIV – How to Rig Research: Surgisphere Part I

It was in these very moments in late May when public health officials lost all credibility—a credibility that cannot be restored without major changes taking place. Despite most evidence pointing to a likelihood of HCQ efficacy, they made their call on the back of data supposedly tucked away in a database that nobody had verified, declared it definitive, then swiftly pushed for policy changes around the world.

Read More »

Another New York State Supreme Court Justice Ivermectin Order Helping 81-Year-Old Farmer

Ivermectin, a medicine for parasites, has been around for four decades. While not authorized for use against COVID-19, dozens of studies show materially positive results. At well-established human dosage levels, the drug is safe: hundreds of millions of people are treated with it every year mostly in the tropics for various parasite-borne diseases, such as River Blindness in Nigeria.

Read More »

The Chloroquine Wars Part XIII -A Clockwork Orange Man

Immediately following HCQ’s Trump moment, the media went on an all-out blitz to associate the topic of HCQ with a sense of fear. Fear of Trump, fear of death, fear of incompetence, fear of opposing scientific authorities, fear of using medicine needed by somebody else, and fear of the unknown. And the campaign of fear didn’t stop there.

Read More »